Statins plus renin-angiotensin system inhibitors
Statins plus renin-angiotensin system inhibitors has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Aug 3, 2026: “Secondary prevention of myocardial infarction in people with dementia: a multi-jurisdictional retrospective cohort study in Asia, Europe and the USA”.
1 paper studies it1 findingUpdated
“Using a statin and RASI without beta-blockers resulted in similar all-cause mortality to using all three (HR 1.16; 95% CI, 0.97-1.39)”
- 1 lab in 1 country
- Funder: Department of Health and Human Services, State Government of Victoria
- 1 of 1 finding with company ties
- Humans1
What did studies of Statins plus renin-angiotensin system inhibitors find?
1Studies of Statins plus renin-angiotensin system inhibitors measured 1 outcome; the most studied are mortality (1 study).
Mortality
no changein humans1HR 1.16
1 study
Mortality
no changein humans1HR 1.16
Statins plus renin-angiotensin system inhibitors were not clearly linked with mortality in humans (without beta-blockers, compared with all three medications, in people with dementia) (HR 1.16; 95% CI 0.97-1.39).
“Using a statin and RASI without beta-blockers resulted in similar all-cause mortality to using all three (HR 1.16; 95% CI, 0.97-1.39)”
Humanswithout beta-blockers, compared with all three medications, in people with dementia
Age and ageing